Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860373 | 0.86 | GRM5 (0.73) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL3860067 | 0.85 | GRM5 (1.00) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL23853820 | 0.79 | RAB9A (0.44) | GRM5RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL3863866 | 0.78 | GRM5 (0.89) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL8283072 | 0.78 | GRM5 (0.79) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL2767963 | 0.77 | KDM4E (0.56) | GRM5RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL3862751 | 0.76 | GRM5 (0.75) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL3870512 | 0.75 | GRM5 (0.74) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL3860869 | 0.75 | GRM5 (1.00) | GRM5RAB9ANPC1TP53POLB | |
| SCHEMBL3868972 | 0.75 | GRM5 (0.73) | GRM5RAB9ANPC1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715867-A4 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| CN-1933838-A | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1715867-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GABRA5 | GRM5 1/4885RAB9A 1748/4885NPC1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.